Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 7kWORD 21k
6 February 2017
E-009141/2016(ASW)
Answer given by Mr Andriukaitis on behalf of the Commission
Question reference: E-009141/2016

The Commission addresses the prevention and management of chronic diseases in a holistic manner, including by addressing the risk factors which are common to various diseases.

In this context, and taking into account the responsibilities of the Member States for the definition of their health policy, the Commission does not intend to shape specific strategies on single diseases. Instead, the Commission supports Member States in their efforts to tackle chronic diseases and disorders, including heart failure. The Commission has presented such action at a recent event on heart failure hosted in the European Parliament in October 2016(1).

The Commission is supporting a joint action on Chronic Diseases (CHRODIS)(2) which has developed an IT platform(3) with best practices, including in the area of heart health. This joint action works on a training programme for managers of multi-morbid patients(4), reflecting the integrated approach to chronic diseases.

Furthermore, over EUR 4 billion have been devoted to support 2300 research projects on chronic diseases under the Horizon 2020 Programme(5). Of these, 208 projects for over EUR 328 million are related to different areas of cardiovascular research. In particular, 18 projects worth EUR 29.6 million address heart failure research. For instance, the ‘SCIENCE’ project aims to develop a stem cell-based therapy to improve myocardial function in patients with ischemic heart disease and heart failure(6), and the ‘HEARTEN’ project focused on design, development and validation of an ICT cooperative environment to improve heart failure management(7). More information about current funding opportunities can be obtained at the Research and Innovation Participant Portal(8).

(1)http://www.healthpolicypartnership.com/meps-launch-written-declaration-heart-failure/
(2)www.chrodis.eu
(3)http://platform.chrodis.eu/ (requires registration)
(4)http://chrodis.eu/our-work/06-multimorbidity/wp06-activities/training-programme/
(5)Horizon 2020, the framework Programme for Research and Innovation (2014-2020) — COM(2011)809, 30/11/2014.
(6)http://stemcellscience.dk
(7)http://www.hearten.eu/
(8)http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/index.html

Legal notice